Liquid Biopsies Redefine Cancer Care
Biotech Primer
Expert-Led Life Sciences Training and Certifications for Non-Scientists to Advance Your Career
by Emma Bardsley PhD
The in vitro diagnostics (IVD) market, already valued at USD $102 billion in 2024, is on the brink of transformation, driven by the surge in liquid biopsy technologies. With a predicted CAGR of 5.2%, this segment is poised to reach USD $132 billion by 2029, fueled by the escalating prevalence of cancer, the?fastest-growing market segment.
Why It Matters
By 2040, cancer diagnoses are expected to escalate to 29.5 million cases annually, with deaths reaching 16.4 million, underscoring the critical need for early detection. The oncology IVD segment, projected to grow by 48% by 2033, highlights the anticipated advancements in technologies aimed at improving cancer diagnoses.
Biotech Primer Inc. provides engaging, interactive training courses tailored for non-scientists in the Biotechnology, Pharmaceutical, Molecular Diagnostics and Medical Device sectors. These courses, developed by industry experts, simplify complex scientific and regulatory concepts for professionals seeking to navigate and contribute effectively to the healthcare sector. With flexible learning options like on-demand online classes and live sessions, Biotech Primer has educated over 150,000 professionals since 2001, making it a go-to resource for understanding the science behind healthcare innovation.